Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Venetoclax + HMA in R/R AML and High-risk MDS
NCT06536959Phase 2Recruiting
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoints: Complete remission rate at Cycle 2, Complete minimal residual disease (MRD) Response Rate at Cycle 2 and 1 more. Started Jul 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06536959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06536959.